1. Docetaxel in combination with hormone therapy for men with advanced prostate cancer
Earlier this month results from a phase 3 clinical trial, the CHAARTED trial, were published in the New England Journal of Medicine. The study, by Sweeney et al., involved almost 800 men diagnosed with hormone-sensitive metastatic (advanced) prostate cancer. The trial assessed whether providing hormone therapy plus docetaxel chemotherapy would result in longer overall survival than with hormone-therapy alone. The authors reported men with advanced prostate cancer were found to live up to 13.6 months longer with docetaxel in addition to hormone therapy. The investigators also did additional sub-analysis of those with high-volume disease (where prostate cancer had spread to four or more locations in the body). In this subgroup, men who were given docetaxel in combination with hormone therapy had an even greater improvement in survival, living 17 months longer than those given hormone therapy alone. The authors concluded that six cycles of docetaxel at the beginning of ADT for metastatic prostate cancer resulted in significantly longer overall survival than that with ADT alone. Prostate Cancer UK has some more information on the article here.